INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26101, 27312, 'Sotalol', 'Hyperthyroidism', 'When beta-adrenergic receptor blocking agents (aka beta-blockers) are used to alleviate symptoms of hyperthyroidism such as tachycardia, anxiety, tremor and heat intolerance, abrupt withdrawal can exacerbate thyrotoxicosis or precipitate a thyroid storm.  To minimize this risk, cessation of beta-blocker therapy, when necessary, should occur gradually with incrementally reduced dosages over a period of 1 to 2 weeks.  Patients should be advised not to discontinue treatment without first consulting with the physician.  Close monitoring is recommended during and after therapy withdrawal.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26102, 1426, 'Sotalol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26103, 27312, 'Sotalol', 'Myasthenia Gravis', 'Beta-adrenergic receptor blocking agents (aka beta-blockers) may potentiate muscle weakness consistent with certain myasthenic symptoms such as diplopia, ptosis, and generalized weakness.  Several beta-blockers have been associated rarely with aggravation of muscle weakness in patients with preexisting myasthenia gravis or myasthenic symptoms.  Use cautiously in patients with myasthenia gravis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26104, 1426, 'Sotalol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26105, 27312, 'Sotalol', 'Pheochromocytoma', 'Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.  In patients with pheochromocytoma, an alpha-blocking agent should be initiated prior to the use of any beta-blocking agent.  Caution should be taken in the administration of these agents to patients suspected of having pheochromocytoma.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26106, 1426, 'Sotalol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26107, 27312, 'Sotalol', 'Psoriasis', 'The use of beta-blockers in psoriatic patients should be carefully weighed since the use of these agents may cause an aggravation in psoriasis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26108, 1426, 'Sotalol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26109, 27312, 'Sotalol', 'Tachycardia', 'Beta-adrenergic blockade in patients with Wolff-Parkinson-White syndrome and tachycardia has been associated with severe bradycardia requiring treatment with a pacemaker.  In one case, this result was reported after an initial dose of 5 mg propranolol.  The use of beta-adrenergic receptor blocking agents (aka beta-blockers) should be administered cautiously in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26110, 1426, 'Sotalol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26111, 27312, 'Sotalol', 'Prinzmetal''s variant angina', 'Agents with non-selective beta-blocking activity may provoke chest pain in patients with Prinzmetal''s variant angina.  the use of non-selective beta blockers is not recommended in these patients.  Caution should be taken in the administration of these agents to patients suspected of having Prinzmetal''s variant angina.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26112, 0, 'Solriamfetol', 'Cardiotoxicity', 'Solriamfetol increases systolic blood pressure, diastolic blood pressure, and heart rate in a dose-dependent fashion.  It is recommended to exercise caution when treating patients at higher risk of cardiovascular toxicities, particularly patients with known cardiovascular and cerebrovascular disease, preexisting hypertension, and patients with advanced age.  Assess blood pressure and control hypertension before initiating treatment and monitor blood pressure regularly during treatment.  Periodically reassess the need for continued therapy with solriamfetol and treat new-onset hypertension and exacerbations of preexisting hypertension according to clinical guidelines.  If a patient experiences increases in blood pressure or heart rate that cannot be managed with dose reduction or other appropriate medical intervention, consider treatment discontinuation.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26113, 0, 'Solriamfetol', 'Psychotic Disorders', 'The use of solriamfetol may cause adverse psychiatric reactions, including anxiety, insomnia, and irritability.  It is recommended to exercise caution when treating patients who have a history of psychosis or bipolar disorders.  Observe patients treated with solriamfetol for the possible emergence or exacerbation of psychiatric symptoms and consider dose reduction or discontinuation of treatment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26114, 0, 'Solriamfetol', 'Kidney Diseases', 'The primary route of solriamfetol elimination is via urinary excretion.  Dosage adjustment is not required for patients with mild renal impairment.  Dosage adjustment is recommended for patients with moderate to severe renal impairment.  Solriamfetol is not recommended for patients with end-stage renal disease.  An average of 21% of solriamfetol is removed by hemodialysis.  Patients with moderate or severe renal impairment may be at a higher risk of increases in cardiovascular adverse events and psychiatric symptoms because of the prolonged half-life.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26115, 14126, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26116, 14620, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26117, 18462, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26118, 20055, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26119, 20056, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26120, 20434, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26121, 20538, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26122, 23043, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26123, 23168, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26124, 23831, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26125, 26834, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26126, 27217, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26127, 27218, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26128, 27220, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26129, 27221, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26130, 27222, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26131, 27223, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26132, 28182, 'Sofosbuvir', 'IMMUNE SUPPRESSION', 'HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death.  Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive).  HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients.  All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy.  Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26133, 14126, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26134, 14620, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26135, 18462, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26136, 20055, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26137, 20056, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26138, 20434, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26139, 20538, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26140, 23043, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26141, 23168, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26142, 23831, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26143, 26834, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26144, 27217, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26145, 27218, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26146, 27220, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26147, 27221, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26148, 27222, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26149, 27223, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26150, 28182, 'Sofosbuvir', 'Hepatic Insufficiency', 'Sofosbuvir is extensively metabolized in the liver.  The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis.  No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26151, 14126, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26152, 14620, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26153, 18462, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26154, 20055, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26155, 20056, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26156, 20434, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26157, 20538, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26158, 23043, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26159, 23168, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26160, 23831, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26161, 26834, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26162, 27217, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26163, 27218, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26164, 27220, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26165, 27221, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26166, 27222, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26167, 27223, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26168, 28182, 'Sofosbuvir', 'Kidney Diseases', 'The safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis.  No dosage recommendation can be given for patients with severe renal impairment or ESRD.  No dosage adjustment is necessary for patients with mild or moderate renal impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26169, 27304, 'Sorafenib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26170, 27305, 'Sorafenib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26171, 10718, 'Sorbitol', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26172, 23526, 'Sorbitol', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26173, 27308, 'Sorbitol', 'Inflammatory Bowel Diseases', 'The use of laxatives is contraindicated in patients with inflammatory bowel disease.  Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26174, 10718, 'Sorbitol', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26175, 23526, 'Sorbitol', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26176, 27308, 'Sorbitol', 'Intestinal Obstruction', 'The use of laxatives is contraindicated in patients with intestinal obstruction disorders.  Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation.  Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26177, 10718, 'Sorbitol', 'Renal Insufficiency', 'The use of sorbitol solution for urologic irrigation is contraindicated in patients with anuria.  In addition, sorbitol irrigation should be administered cautiously in patients with cardiopulmonary or renal dysfunction.  Irrigating fluids may enter the systemic circulation, and absorption of large quantities of fluids containing sorbitol may significantly alter cardiopulmonary and renal dynamics.  Before and during the urologic procedure, cardiovascular and renal status should be monitored, particularly if the volume absorbed is expected to produce a substantial expansion of the intravascular fluid (e.g., via opened prostatic veins in transurethral prostatectomies).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26178, 23526, 'Sorbitol', 'Renal Insufficiency', 'The use of sorbitol solution for urologic irrigation is contraindicated in patients with anuria.  In addition, sorbitol irrigation should be administered cautiously in patients with cardiopulmonary or renal dysfunction.  Irrigating fluids may enter the systemic circulation, and absorption of large quantities of fluids containing sorbitol may significantly alter cardiopulmonary and renal dynamics.  Before and during the urologic procedure, cardiovascular and renal status should be monitored, particularly if the volume absorbed is expected to produce a substantial expansion of the intravascular fluid (e.g., via opened prostatic veins in transurethral prostatectomies).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26179, 27308, 'Sorbitol', 'Renal Insufficiency', 'The use of sorbitol solution for urologic irrigation is contraindicated in patients with anuria.  In addition, sorbitol irrigation should be administered cautiously in patients with cardiopulmonary or renal dysfunction.  Irrigating fluids may enter the systemic circulation, and absorption of large quantities of fluids containing sorbitol may significantly alter cardiopulmonary and renal dynamics.  Before and during the urologic procedure, cardiovascular and renal status should be monitored, particularly if the volume absorbed is expected to produce a substantial expansion of the intravascular fluid (e.g., via opened prostatic veins in transurethral prostatectomies).', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26180, 10718, 'Sorbitol', 'Diabetes Mellitus', 'Sorbitol is converted to glucose in the body.  The use of sorbitol is not recommended as an alternative sweetener in patients with diabetes.  Sorbitol is one of the end products of glucose metabolism that results in some of the late complications of diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26181, 23526, 'Sorbitol', 'Diabetes Mellitus', 'Sorbitol is converted to glucose in the body.  The use of sorbitol is not recommended as an alternative sweetener in patients with diabetes.  Sorbitol is one of the end products of glucose metabolism that results in some of the late complications of diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26182, 27308, 'Sorbitol', 'Diabetes Mellitus', 'Sorbitol is converted to glucose in the body.  The use of sorbitol is not recommended as an alternative sweetener in patients with diabetes.  Sorbitol is one of the end products of glucose metabolism that results in some of the late complications of diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26183, 10718, 'Sorbitol', 'Water-Electrolyte Imbalance', 'Shift of sodium-free intracellular fluid into the extracellular compartment following systemic absorption of sorbitol irrigation may lower serum sodium concentration and aggravate preexisting-existing hyponatremia.  Excessive loss of water and electrolytes may may also cause hypernatremia.  Sustained diuresis from transurethral irrigation with sorbitol irrigation may obscure and intensify inadequate hydration or hypovolemia.  Patients with sodium imbalances or dehydration should be closely monitored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26184, 23526, 'Sorbitol', 'Water-Electrolyte Imbalance', 'Shift of sodium-free intracellular fluid into the extracellular compartment following systemic absorption of sorbitol irrigation may lower serum sodium concentration and aggravate preexisting-existing hyponatremia.  Excessive loss of water and electrolytes may may also cause hypernatremia.  Sustained diuresis from transurethral irrigation with sorbitol irrigation may obscure and intensify inadequate hydration or hypovolemia.  Patients with sodium imbalances or dehydration should be closely monitored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26185, 27308, 'Sorbitol', 'Water-Electrolyte Imbalance', 'Shift of sodium-free intracellular fluid into the extracellular compartment following systemic absorption of sorbitol irrigation may lower serum sodium concentration and aggravate preexisting-existing hyponatremia.  Excessive loss of water and electrolytes may may also cause hypernatremia.  Sustained diuresis from transurethral irrigation with sorbitol irrigation may obscure and intensify inadequate hydration or hypovolemia.  Patients with sodium imbalances or dehydration should be closely monitored.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26186, 2944, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26187, 4825, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26188, 4995, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26189, 9310, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26190, 10632, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26191, 10633, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26192, 13015, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26193, 13016, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26194, 20758, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26195, 20759, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26196, 23243, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26197, 23244, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26198, 27094, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26199, 27214, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (26200, 27249, 'Solifenacin', 'Gastrointestinal Diseases', 'The use of solifenacin is contraindicated in patients with gastric retention.  Caution is advised even when using this agent in patients with decreased gastrointestinal motility.', '3', '', 'DDInter', 0);
